Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).

"CONFLICTS OF INTEREST Mazen Noureddin consults and received grants from Gilead, GlaxoSmithKline, Madrigal, Novo Nordisk, Takeda, and Terns. He consults, advises, and owns stock in Cytodyn. He consults and advises 89BIO, Altimmune, Boehringer Ingelheim, Merck, and Perspecturm. He has received grants and owns stock in Viking. He advises Blade, cohBar, EchoSens, Fractyl, Intercept, NorthSea, Pfizer, Siemens, and Roche Diagnostics. He has received grants from Allergan, Bristol Myers Squibb, Conatus, Corcept, Enanta, Galmed, Galectin, Genfit, Madrigal, Novartis, Pfizer, Shire, and Zydus. He owns stock in Anaetos, ChronWell, Cima, and Rivus Pharma. Rebeca Mayo is employed by OWL Metabolomics. Ibon Martínez-Arranz is employed by OWL Metabolomics. Itziar Mincholé is employed by OWL Metabolomics. Jesus M. Banales consults and advises OWL Metabolomics. He consults and received grants from Albireo. He received grants and is on the speakers’ bureau for Incyte. He consults for CymaBay, Ikan Biotech, and QED Therapeutics. He is on the speakers’ bureau for Intercept. Kenneth Cusi consults and received grants from Novo Nordisk. He consults for Aligos, Allergan, Altimmune, Arrowhead, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Coherus, Covance, Eli Lilly, Fractyl, Genentech, Gilead, Hanmi, Intercept, Janssen, Madrigal, Pfizer, Prosciento, Sagimet, and Siemens. He received grants from Cirius, Echosens, Inventiva, LabCorp, National Institute of Health, Nordic Bioscience, Novartis, Poxel, and Zydus. Manuel Romero-Gómez advises and received grants from Gilead, Intercept, and Siemens. He consults for Galmed. He advises AbbVie, Alfa-Sigma, Madrigal, Novo Nordisk, and Pfizer. He received grants from Thera Therapeutics. Tatyana Kushner advises and received grants from Gilead. She consults for AbbVie. She advises Bausch and GlaxoSmithKline. Pablo Ortiz is employed by and owns stock in OWL Metabolomics. He is employed by Biosfer Teslab and Health in Code. Stephen A. Harrison consults, advises, is involved with trials, received grants, and owns stock in Akero, Galectin, GENFIT, Hepion, and NGM Bio. He consults, advises, is involved with trials, and received grants from Axcella, Gilead, Intercept, Madrigal, and Poxel. He consults, advises, received grants, and owns stock in NorthSea Therapeutics. He consults, advises, and is involved with trials for Terns. He consults, advises, and received grants from HighTide, Novartis, Novo Nordisk, and Sagimet. He consults, advises, and owns stock in HistoIndex, Metacrine, and Sonic Incytes. He consults, received grants, and owns stock in Cirius. He consults, is involved with trials, and received grants from ENYO and Viking. He is involved with trials and received grants from Genentech. He consults and is involved with trials for Ionis. He consults and received grants from CiVi, CymaBay, Galmed, and Pfizer. He consults and owns stock in Hepta Bio. He consults and advises for Altimmune, Echosens North America, Foresite Labs, and Medpace. He advises and owns stock in ChronWell. He consults for AgomAb, Alentis, Aligos Therapeutics, Alimentiv, Blade, Bluejay, Boston Pharmaceuticals, Boxer Capital, Can-Fite BioPharma, the Chronic Liver Disease Foundation (CLDF), CohBar, Corcept, Fibronostics, Fortress Biotech, Galecto, Gelesis, Glaxo Smith Kline, GNS Healthcare, GRI Bio, Hepagene, Indalo, Inipharm, Innovate Biopharmaceuticals, Kowa Research Institute, Merck, MGGM, NeuroBo, Nutrasource, Perspectum, Piper Sandler, Prometic (now Liminal BioSciences), Ridgeline Therapeutics, Silverback, and Zafgen (now Larimar). He advises Arrowhead BVF Partners, Humana, and Pathai. He received grants from Bristol Myers Squibb, Conatus, Immuron, and Second Genome. Quentin M. Anstee, on behalf of Newcastle University, consults and advises for Alimentiv, Akero, AstraZeneca, Axcella, 89Bio, Boehringer Ingelheim, Bristol Myers Squibb, Galmed, GENFIT, Genentech, Gilead, GlaxoSmithKline, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janssen, Madrigal, Medpace, Merck, NGM Bio, Novartis, Novo Nordisk, PathAI, Pfizer, Prosciento, Poxel, Resolution Therapeutics, Ridgeline Therapeutics, Roche, RTI, Shionogi, and Terns. He is on the speakers’ bureau for Fishawack, Integritas Communications, Kenes, Novo Nordisk, Madrigal, Medscape, and Springer Healthcare. He received grants from AstraZeneca, Boehringer Ingelheim, and Intercept. He holds intellectual property rights with Elsevier, Ltd. He serves as coordinator of the IMI2 LITMUS consortium. Arun J. Sanyal consults, advises, and received grants from AstraZeneca, Boehringer Ingelhiem, Bristol Myers Squibb, Eli Lilly, Fractyl, Gilead, Inventiva, Madrigal, Mallinckrodt, Merck, Novartis, Novo Nordisk, and Pfizer. He consults and advises 89 Bio, Albrio, Alnylam, Amgen, Covance, Genetech, GenFit, Hemoshear, HistoIndex, Intercept, Jannsen, NGM Bio, Path AI, Poxel, Prosciento, Regeneron, Roche, Salix, Sequana, Terns, and Tiziana. He advises Akero, Axcella, Blade, Eisai, Hanmi, LG, Pharmanest, Pliant, Siemens, Takeda, Thera Technologies, Valeant, and Zealand Pharma. He received grants from Echosence-Sandhill, Galmed, Madrigal, Merck, Viking, and Zydus. He owns stock in Durect, Exhalenz, Galmed, GENFIT, Hemoshear, Rivis, Siemens, and Tiziana. He has other interests with Elsevier and UpToDate. The remaining authors (Emily Truong, Marco Arrese, María Teresa Arias-Loste, Radan Bruha, Paula Iruzubieta, Rocio Aller, Javier Ampuero, José Luis Calleja, Luis Ibañez-Samaniego, Patricia Aspichueta, Antonio Martín-Duce, Javier Crespo, and José M. Mato) have no conflicts to report."

"FUNDING INFORMATION Marco Arrese received funding from Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT) under grant agreement No. 1191145. Quentin M. Anstee is supported by the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking, under grant agreement No. 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. He is a Newcastle NIHR Biomedical Research Centre investigator."